AVITA Medical, Inc. (51KA.F)
Chart Events
Performance Outlook
| Previous Close | 12.30 |
| Open | 12.30 |
| Bid | 12.20 x N/A |
| Ask | 12.30 x N/A |
| Day's Range | 12.30 - 12.30 |
| 52 Week Range | 4.30 - 13.50 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 319.303M |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | Feb 23, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.60 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 51KA.F
Related Research
- Zacks
Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review
The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.
- GlobeNewswire
AVITA Medical Appoints New Non-Executive Member to the Board of Directors
VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, announced today the appointment of Robert McNamara to its Board of Directors, effective April 1, 2023. Mr. McNamara is an accomplished senior executive with over 25 years of leadership experience in public and privat
- Zacks
What Makes Avita Medical Inc. (RCEL) a Good Fit for 'Trend Investing'
Avita Medical Inc. (RCEL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
